Unity Biotechnology (UBX) Expected to Announce Earnings on Tuesday

Unity Biotechnology (NASDAQ:UBX) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). On average, analysts expect Unity Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Unity Biotechnology Stock Performance

Shares of Unity Biotechnology stock traded down $0.06 during trading hours on Tuesday, reaching $1.02. The company’s stock had a trading volume of 46,937 shares, compared to its average volume of 235,704. The company’s 50 day simple moving average is $1.26 and its 200 day simple moving average is $1.42. The stock has a market cap of $17.47 million, a P/E ratio of -0.77 and a beta of 1.28. Unity Biotechnology has a one year low of $0.85 and a one year high of $3.10.

Analysts Set New Price Targets

A number of research firms have recently commented on UBX. Chardan Capital reissued a “buy” rating and issued a $4.00 price objective on shares of Unity Biotechnology in a research note on Wednesday, April 23rd. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Unity Biotechnology in a research report on Wednesday, April 23rd.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.